National surveillance of Helicobacter pylori eradication therapy in Denmark. Results from registration of 34,582 prescriptions.
BACKGROUND
We wanted to characterize the use of Helicobacter pylori eradication therapy in Denmark (5,227,862 inhabitants).


METHODS
All H. pylori eradication treatments from a nationwide database including all redeemed drug prescriptions in the period January 1994 to June 1996 were identified. So were all outpatients receiving a drug prescription for H. pylori eradication.


RESULTS
We recorded 34,582 prescriptions for H. pylori eradication therapy given to 28,784 patients. The incidence of new consumers was 220 per 10(5) inhabitants per year, with a maximum at 70-79 years of age. Eighty-six per cent of the patients had only one treatment course. In 16% of the eradication therapies, nonsteroid anti-inflammatory drugs had been prescribed within the previous 3 months, and 45% had an anti-ulcer drug prescribed 1-12 months after the H. pylori eradication therapy. Consumption of antibiotics used for H. pylori eradication accounted for 1.4% of the total consumption of antibiotics.


CONCLUSIONS
The incidence of H. pylori eradication therapy was fairly stable but with changes in the pattern of drug regimens used. Anti-ulcer drugs were often given after H. pylori eradication therapy, suggesting an inappropriate use of treatment.
Juul
K V
KV
The Danish National Board of Health, Copenhagen.
Thomsen
O O
OO
Nissen
A
A
Hallas
J
J
Kolmos
H J
HJ
Funch-Jensen
P
P
Lauritsen
K
K
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000658:Amoxicillin / Q000008:administration & dosage*; D000863:Antacids / Q000008:administration & dosage*; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D001729:Bismuth / Q000008:administration & dosage*; D002648:Child; D003718:Denmark; D011307:Drug Prescriptions; D004359:Drug Therapy, Combination; D005260:Female; D019538:Health Care Surveys; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D006635:Histamine H2 Antagonists / Q000627:therapeutic use*; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage; D018942:Macrolides; D008297:Male; D008875:Middle Aged; D010406:Penicillins / Q000008:administration & dosage*; D054328:Proton Pump Inhibitors; D013754:Tetracyclines / Q000008:administration & dosage*
D000863:Antacids; D000900:Anti-Bacterial Agents; D006635:Histamine H2 Antagonists; D007093:Imidazoles; D018942:Macrolides; D010406:Penicillins; D054328:Proton Pump Inhibitors; D013754:Tetracyclines; D000658:Amoxicillin; D001729:Bismuth